Vascular Laser Treatment Near Seoul at RE:BERRY Incheon Airport

Why Different Vessels Need Different Wavelengths

Vascular lesions are not homogeneous. A single patient may present with superficial telangiectasia (0.1-0.3mm diameter, within 0.5mm of the skin surface), deeper reticular veins (0.5-2mm diameter, 1-3mm deep), and diffuse erythema caused by sub-clinical microvascular dilation invisible to the naked eye. Each vessel type has an optimal treatment wavelength determined by two factors: the depth of laser penetration and the pulse duration needed for thermal relaxation matching. Superficial capillaries with diameters under 0.3mm have thermal relaxation times of 0.01-1 milliseconds, requiring short-pulse lasers. Deeper, larger vessels with 1-2mm diameters have thermal relaxation times of 10-100 milliseconds, requiring longer pulse durations. The 595nm pulsed dye laser excels at superficial vessels because this wavelength is near the oxyhemoglobin absorption peak and penetrates 0.5-1.2mm. The 1064nm Nd:YAG penetrates 4-6mm, reaching deeper vessels that 595nm light cannot access. This physical reality is why no single wavelength can treat all vascular lesions optimally.

Clinical Evidence for Multi-Wavelength Superiority

A growing body of evidence supports multi-wavelength vascular laser protocols over single-device approaches. Bernstein (2008) compared sequential 595nm PDL followed by 1064nm Nd:YAG against PDL alone for facial telangiectasia and found that the dual-wavelength group achieved 81% clearance versus 57% for PDL alone after 3 sessions. The mechanism is straightforward: PDL clears the superficial vessel layer, exposing deeper vessels to the subsequent Nd:YAG wavelength that can now reach them without absorption by the superficial layer. This sequential approach is routine at Korean vascular laser clinics like RE:BERRY, where physicians are trained to use multiple devices in a single session rather than relying on a single laser. For rosacea specifically, the addition of IPL broadband light addresses the diffuse background erythema component that neither PDL nor Nd:YAG optimally treats. IPL’s broad spectrum (500-1200nm) and large spot size allow rapid treatment of extensive areas of sub-clinical erythema.

Rosacea Pathophysiology and Long-Term Management

Rosacea is fundamentally a neurovascular disorder, not simply a cosmetic issue of visible blood vessels. The pathophysiology involves upregulation of cathelicidin (LL-37), kallikrein-5 serine protease, and VEGF-mediated angiogenesis that continuously creates new abnormal vessels. This is why vascular laser alone, while highly effective at clearing existing vessels, does not cure rosacea — new vessels form through ongoing VEGF stimulation. Long-term management requires both periodic laser maintenance (every 6-12 months) and barrier-strengthening interventions. Rejuran polynucleotide provides a unique adjunct by stimulating fibroblast proliferation and extracellular matrix repair, strengthening the dermal support structure around blood vessels and potentially reducing the rate of new telangiectasia formation. This integrated approach — vascular clearance plus barrier repair — represents the current best practice in Korean rosacea management.

Dynamic Cooling and Epidermal Protection

Modern vascular lasers employ dynamic cooling devices (DCD) that spray cryogen (tetrafluoroethane, -26 degrees Celsius) onto the skin surface 20-50 milliseconds before each laser pulse. This creates a thermal gradient: the epidermis cools to 0-5 degrees while the deeper dermal vessels remain at body temperature. When the laser pulse fires, the cooled epidermis is protected from thermal damage while the vascular target absorbs full energy. This technology is particularly critical for Fitzpatrick III-V skin types where competing melanin absorption in the epidermis increases burn risk. Korean vascular laser specialists fine-tune DCD spray duration, delay time, and cryogen volume for each patient’s skin type — a level of precision that dramatically reduces complication rates compared to standardized parameters.

References: Bernstein EF. J Cosmet Laser Ther. 2008;10(1):36-42. doi:10.1080/14764170701817082 | Clark SM et al. Lasers Surg Med. 2004;34(3):171-176. doi:10.1002/lsm.20024 | Tanghetti EA. J Clin Aesthet Dermatol. 2016;9(1):16-25. doi:10.25251/skin.3.supp.132